177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, non-controlled, non-randomized study to assess the safety and measure
image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic
castration-resistant prostate cancer (mCRPC) who will undergo radioliagnd therapy using
177Lu-EB-PSMA-617. All patients underwent whole-body 68Ga-PSMA PET/CT for selection and
accepted intravenous injection with single dose 0.80-1.1 GBq (21.5-30 mCi) of
177Lu-EB-PSMA-617 within one week, then monitored at 2, 24, 72, 120 and 168 h after
177Lu-EB-PSMA617 administration with serial whole body planar and SPECT/CT imaging.
Phase:
Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
National Institute for Biomedical Imaging and Bioengineering (NIBIB)